SOLICITATION NOTICE
R -- CENTERS FOR MEDICARE AND MEDICAID SERVICES COST- EFFECTIVENESS ANALYSIS
- Notice Date
- 7/10/2004
- Notice Type
- Solicitation Notice
- NAICS
- 541611
— Administrative Management and General Management Consulting Services
- Contracting Office
- Department of Health and Human Services, Program Support Center, Division of Acquisition Management, Parklawn Building Room 5-101 5600 Fishers Lane, Rockville, MD, 20857
- ZIP Code
- 20857
- Solicitation Number
- Reference-Number-04R000206
- Response Due
- 7/25/2004
- Archive Date
- 8/9/2004
- Point of Contact
- Chris Ganey, Contract Specialist, Phone 301-443-4379, Fax 301-443-3849,
- E-Mail Address
-
cganey2@psc.gov
- Description
- The Agency for Health Research and Quality (DHHS), through the Program Support Center, intends to negotiate a sole-source award with the University of Sheffield, Sheffield, England . Purpose: The Centers for Medicare and Medicaid Services (CMS) has requested a cost-effectiveness analysis of disease-modifying biologics used to treat Rheumatoid Arthritis (RA) in the United States. Specifically, CMS is interested in the incremental cost-effectiveness of the self-administered immuno-modulating drugs etanercept, adalimumab, and anakinra which will be covered under a Medicare demonstration program mandated by Section 641 of the Medicare Prescription Drug Improvement and Modernization Act (MMA) ? relative to that of physician-administered infliximab, which is currently covered under Medicare Part B. An analysis of the cost-effectiveness of the demonstration project that extends coverage to these therapies is required under the MMA. CMS is also interested in the cost-effectiveness of these disease-modifying drugs relative to conventional RA therapy. The Technology Assessment Program provides scientific oversight for technology assessments, cost-effectiveness models and related studies that are produced through contracts with outside organizations. The costs of the contract are paid with funds transferred from CMS to AHRQ through an IAA. The Office of Research, Development and Information of the Centers for Medicare and Medicaid Services (CMS) has asked AHRQ to provide a cost-effectiveness model of disease-modifying therapies for the treatment of RA. The final report provided under this contract will be used to inform the evaluation of the demonstration project that will pay for self-administered drugs and biologicals prescribed as replacements for drugs currently covered under Medicare Part B. A Report to Congress that incorporates the results from this study will be completed by CMS staff and is due June 2006. Sheffield?s cost-effectiveness model is the only model of RA drugs that contains all of the drugs of interest and used state-of-the-art probabilistic sensitivity analyses where there are no current conflicts regarding the results of research. THE PROPOSED SIMPLIFIED ACQUISITION ACTION IS FOR SUPPLIES OR SERVICES FOR WHICH THE GOVERNMENT INTENDS TO SOLICIT AND NEGOTIATE WITH ONLY ONE SOURCE UNDER AUTHORITY OF FAR 13.106-1 INTERESTED PERSONS MAY IDENTIFY THEIR INTEREST AND CAPABILITY TO RESPOND TO THE REQUIREMENT OR SUBMIT PROPOSALS WITHIN 7 DAYS AFTER THE DATE OF PUBLICATION OF THIS NOTICE. A DETERMINATION BY THE GOVERNMENT NOT TO COMPETE THIS PROPOSED SIMPLIFIED ACQUISITION BASED UPON RESPONSES TO THIS NOTICE IS SOLELY WITHIN THE DISCRETION OF THE GOVERNMENT. INFORMATION RECEIVED WILL NORMALLY BE CONSIDERED SOLELY FOR THE PURPOSE OF DETERMINING WHETHER TO CONDUCT A COMPETITIVE PROCUREMENT.
- Record
- SN00618668-W 20040712/040710211538 (fbodaily.com)
- Source
-
FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |